TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Authors: Yardley DA; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.; Tennessee Oncology, Nashville, TN, USA. dyardley@tnonc.com., Arrowsmith ER; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Daniel BR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Eakle J; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Brufsky A; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Drosick DR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Oncology Hematology Care, Cincinnati, OH, USA., Kudrik F; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; South Carolina Oncology Associates, Columbia, SC, USA., Bosserman LD; Wilshire Oncology Medical Group, La Verne, CA, USA., Keaton MR; Augusta Oncology Associates, Augusta, GA, USA., Goble SA; Virginia Cancer Institute, Richmond, VA, USA., Bubis JA; ICON/Cancer Specialists of North Florida, Jacksonville, FL, USA., Priego VM; Center for Cancer and Blood Disorder, Bethesda, MD, USA., Pendergrass K; Kansas City Cancer Center, Overland Park, KS, USA., Manalo Y; Costal Bend Cancer Center, Corpus Christi, TX, USA., Bury M; Cancer Research Consortium of West Michigan, Grand Rapids, MI, USA., Gravenor DS; Family Cancer Center, Memphis, TN, USA., Rodriguez GI; South Texas Oncology Hematology, San Antonio, TX, USA., Inhorn RC; Mercy Hospital, Portland, ME, USA., Young RR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; The Center for Cancer and Blood Disorders, Ft Worth, TX, USA., Harwin WN; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Silver C; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Hainsworth JD; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA., Burris HA 3rd; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Aug; Vol. 164 (3), pp. 649-658. Date of Electronic Publication: 2017 May 15.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-017-4285-6